Neuronetics, Inc. (STIM)
After hours:
| Previous close | 4.0400 |
| Open | 4.0500 |
| Bid | 3.9200 x 100 |
| Ask | 3.9900 x 300 |
| Day's range | 3.9200 - 4.0700 |
| 52-week range | 1.0300 - 5.0700 |
| Volume | |
| Avg. volume | 179,914 |
| Market cap | 118.699M |
| Beta (5Y monthly) | 2.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0500 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in t
ZacksNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
- GlobeNewswire
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees. In accordance with NASDAQ Listing Rule
